https://www.selleckchem.com/pr....oducts/glx351322.htm
ilotinib dose can alleviate the occurrence of hyperbilirubinemia, the effect of MMR is also reduced. Treatment of CML without dose adjustment or discontinuation of nilotinib therapy may be more advantageous. Although reducing the nilotinib dose can alleviate the occurrence of hyperbilirubinemia, the effect of MMR is also reduced. Treatment of CML without dose adjustment or discontinuation of nilotinib therapy may be more advantageous.The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolu
Like
Comment
Share
